NO323720B1 - Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase - Google Patents

Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase Download PDF

Info

Publication number
NO323720B1
NO323720B1 NO19995818A NO995818A NO323720B1 NO 323720 B1 NO323720 B1 NO 323720B1 NO 19995818 A NO19995818 A NO 19995818A NO 995818 A NO995818 A NO 995818A NO 323720 B1 NO323720 B1 NO 323720B1
Authority
NO
Norway
Prior art keywords
amine
compound according
bicyclo
dimethoxy
alkoxy
Prior art date
Application number
NO19995818A
Other languages
English (en)
Norwegian (no)
Other versions
NO995818D0 (no
NO995818L (no
Inventor
Michael R Myers
Wei He
Martin P Maguire
Alfred P Spada
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO995818D0 publication Critical patent/NO995818D0/no
Publication of NO995818L publication Critical patent/NO995818L/no
Publication of NO323720B1 publication Critical patent/NO323720B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/54—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
NO19995818A 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase NO323720B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86445597A 1997-05-28 1997-05-28
US97261497A 1997-11-18 1997-11-18
PCT/US1998/011036 WO1998054158A1 (en) 1997-05-28 1998-05-28 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES

Publications (3)

Publication Number Publication Date
NO995818D0 NO995818D0 (no) 1999-11-26
NO995818L NO995818L (no) 1999-11-26
NO323720B1 true NO323720B1 (no) 2007-06-25

Family

ID=27127839

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19995818A NO323720B1 (no) 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
NO19995819A NO323721B1 (no) 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56lck-tyrosinkinase og farmasoytisk formulering inneholdende det samme, samt anvendelse derav
NO19995817A NO316377B1 (no) 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56<O>lck</O>-tyrosinkinase, farmas degree ytisk blandinginneholdende detsamme samt anvendelse derav

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO19995819A NO323721B1 (no) 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56lck-tyrosinkinase og farmasoytisk formulering inneholdende det samme, samt anvendelse derav
NO19995817A NO316377B1 (no) 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56<O>lck</O>-tyrosinkinase, farmas degree ytisk blandinginneholdende detsamme samt anvendelse derav

Country Status (25)

Country Link
EP (3) EP1001946B1 (enExample)
JP (3) JP2002500675A (enExample)
KR (2) KR100440756B1 (enExample)
CN (3) CN1280572A (enExample)
AP (3) AP1554A (enExample)
AT (3) ATE493389T1 (enExample)
AU (3) AU742739B2 (enExample)
BG (3) BG64444B1 (enExample)
BR (3) BR9809501A (enExample)
CA (3) CA2291750A1 (enExample)
CZ (3) CZ298521B6 (enExample)
DE (3) DE69828607T2 (enExample)
DK (1) DK0991628T3 (enExample)
EA (4) EA004103B1 (enExample)
ES (1) ES2235331T3 (enExample)
HU (2) HUP0002084A3 (enExample)
IL (3) IL133009A0 (enExample)
NO (3) NO323720B1 (enExample)
OA (3) OA11264A (enExample)
PL (3) PL194980B1 (enExample)
PT (1) PT991628E (enExample)
SI (1) SI0991628T1 (enExample)
SK (4) SK158099A3 (enExample)
UA (1) UA57790C2 (enExample)
WO (3) WO1998054158A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159978A (en) * 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
IL133009A0 (en) * 1997-05-28 2001-03-19 Aventis Pharm Prod Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
EP1309596B1 (en) 2000-08-11 2008-02-06 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CN1930128A (zh) 2004-01-16 2007-03-14 惠氏公司 受体酪氨酸激酶抑制剂的喹啉中间体及其合成
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2241557A1 (de) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN101823998B (zh) * 2010-05-05 2015-03-25 江苏利田科技股份有限公司 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP5990187B2 (ja) 2010-12-16 2016-09-07 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2841428B1 (en) 2012-04-24 2018-08-22 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014159690A1 (en) 2013-03-12 2014-10-02 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
MX370099B (es) 2014-03-26 2019-12-02 Astex Therapeutics Ltd Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
KR102691777B1 (ko) 2015-09-23 2024-08-02 얀센 파마슈티카 엔브이 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
WO2018064092A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583793B2 (en) * 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
DE4426373A1 (de) * 1994-07-26 1996-02-01 Bayer Ag 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
ATE338754T1 (de) * 1996-07-19 2006-09-15 Takeda Pharmaceutical Heterocyclische verbindungen, ihre herstellung und verwendung
AU5574798A (en) * 1997-01-21 1998-08-07 Nissan Chemical Industries Ltd. Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
IL133009A0 (en) * 1997-05-28 2001-03-19 Aventis Pharm Prod Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Also Published As

Publication number Publication date
SK157999A3 (en) 2000-06-12
PL195552B1 (pl) 2007-10-31
EP0991628A4 (en) 2000-07-26
UA57790C2 (uk) 2003-07-15
DE69828607D1 (de) 2005-02-17
NO995817D0 (no) 1999-11-26
EA200100575A1 (ru) 2002-02-28
BG104006A (en) 2000-07-31
BG64444B1 (en) 2005-02-28
ES2235331T3 (es) 2005-07-01
IL133007A0 (en) 2001-03-19
CN1261354A (zh) 2000-07-26
BR9809501A (pt) 2000-06-20
JP2002500676A (ja) 2002-01-08
SK158199A3 (en) 2000-06-12
CN1261353A (zh) 2000-07-26
WO1998054158A1 (en) 1998-12-03
AU7803798A (en) 1998-12-30
KR20010013057A (ko) 2001-02-26
EA008136B1 (ru) 2007-04-27
NO995818D0 (no) 1999-11-26
CA2291774A1 (en) 1998-12-03
AU747026B2 (en) 2002-05-09
BR9809172A (pt) 2000-08-01
AP9901709A0 (en) 1999-12-31
JP2002513417A (ja) 2002-05-08
OA11221A (en) 2003-07-16
BR9809515A (pt) 2000-06-20
EP1001945A1 (en) 2000-05-24
SI0991628T1 (en) 2005-06-30
CZ298490B6 (cs) 2007-10-17
DK0991628T3 (da) 2005-05-17
NO995819D0 (no) 1999-11-26
EA004103B1 (ru) 2003-12-25
HUP0002084A2 (hu) 2000-10-28
EP1001945B1 (en) 2011-03-02
AU751188C (en) 2005-06-30
EA199901086A1 (ru) 2000-06-26
SK286084B6 (sk) 2008-03-05
NO995818L (no) 1999-11-26
AU7706298A (en) 1998-12-30
WO1998054156A1 (en) 1998-12-03
HK1028042A1 (en) 2001-02-02
EA199901090A1 (ru) 2000-08-28
PL194980B1 (pl) 2007-07-31
CA2291728A1 (en) 1998-12-03
BG64419B1 (bg) 2005-01-31
AU751188B2 (en) 2002-08-08
BG103965A (en) 2000-07-31
EA002600B1 (ru) 2002-06-27
PL194670B1 (pl) 2007-06-29
KR100425638B1 (ko) 2004-04-03
PL337087A1 (en) 2000-07-31
DE69828607T2 (de) 2006-01-05
EP1001946A1 (en) 2000-05-24
EA007807B1 (ru) 2007-02-27
NO323721B1 (no) 2007-06-25
AP9901710A0 (en) 1999-12-31
DE69842077D1 (de) 2011-02-10
AP1554A (en) 2006-01-18
PL337086A1 (en) 2000-07-31
EP0991628B1 (en) 2005-01-12
CZ418099A3 (cs) 2000-05-17
HUP0004807A2 (hu) 2001-11-28
CN1280572A (zh) 2001-01-17
ATE500233T1 (de) 2011-03-15
EA199901092A1 (ru) 2000-06-26
WO1998054157A1 (en) 1998-12-03
AP1362A (en) 2005-01-19
EP1001946B1 (en) 2010-12-29
BG103963A (en) 2000-07-31
OA11264A (en) 2002-11-19
CZ417999A3 (cs) 2000-05-17
PT991628E (pt) 2005-05-31
AU742739B2 (en) 2002-01-10
EP0991628A1 (en) 2000-04-12
OA11222A (en) 2003-07-16
CA2291750A1 (en) 1998-12-03
BG64445B1 (en) 2005-02-28
AP9901711A0 (en) 1999-12-31
ATE493389T1 (de) 2011-01-15
CZ296845B6 (cs) 2006-07-12
KR100440756B1 (ko) 2004-07-21
IL133009A0 (en) 2001-03-19
IL133007A (en) 2005-06-19
HUP0002084A3 (en) 2000-12-28
NO995819L (no) 1999-11-26
CN1140516C (zh) 2004-03-03
AP1444A (en) 2005-07-18
PL337084A1 (en) 2000-07-31
ATE286886T1 (de) 2005-01-15
CZ298521B6 (cs) 2007-10-24
IL133008A0 (en) 2001-03-19
EP1001946A4 (en) 2000-07-26
NO995817L (no) 1999-11-26
SK158099A3 (en) 2000-06-12
HUP0004807A3 (en) 2001-12-28
EP1001945A4 (en) 2000-07-26
AU7707998A (en) 1998-12-30
CZ415899A3 (cs) 2000-05-17
NO316377B1 (no) 2004-01-19
KR20010039512A (ko) 2001-05-15
JP2002500675A (ja) 2002-01-08
DE69842151D1 (de) 2011-04-14

Similar Documents

Publication Publication Date Title
NO323720B1 (no) Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
US6852712B2 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6482834B2 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
KR100480360B1 (ko) 혈소판-유도된 성장 인자 및/또는 ｐ56ｌｃｋ 티로신 키나제를 억제하는 퀴놀린 및 퀴녹살린 화합물
MXPA99011017A (en) QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck
MXPA99011025A (en) QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck
HUP0002219A2 (hu) Vérlemezke-eredetű növekedési faktor és/vagy p56lck tirozin kináz gátló hatású kinolin és kinoxalinszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények